Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Nov 22;10:1434. doi: 10.3389/fphys.2019.01434

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2019 Shi, Yuan, Wang, Wang, Liu, Tian, Guo, Zhang and Wang.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Effect of oral administration of SPIR on arterial pressure. The MR antagonist SPIR was administered via oral gavage once daily for 7 days in TASK^+/+ (n = 7) and TASK^−/− mice (n = 12). (A,B) Administration of SPIR produced mild decrease in SBP only at specific time points and no obvious decrease in DBP in TASK^+/+ mice. ^*p < 0.05, ^****p < 0.0001 as indicated by two-way ANOVA with Fisher’s LSD post hoc test. (C,D) After treatment with SPIR, SBP and DBP were significantly lowered at each time point over 24 h in TASK^−/− mice. (E–G) Application of SPIR markedly lowered 24-h average SBP and DBP in TASK^−/− mice, with insignificant changes in TASK^+/+ mice. No significant difference was observed in HR between two genotypes after MR blockade. ^**p < 0.01, ^***p < 0.001, ^****p < 0.0001 as indicated by two-way ANOVA with Bonferroni’s multiple comparisons test. MR, mineralocorticoid receptors; SPIR, spironolactone.